Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: Systematic review and meta-analysis

American Journal of Kidney Diseases

Volumn 66, Issue 1, 2015, Pages 69-74

  Wilhelm Leen, Emilee R ^a   Winkelmayer, Wolfgang C ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

anemia; carbohydrate side chain; chronic kidney disease (CKD); darbepoetin alfa (DPO); drug safety; end stage renal disease (ESRD); epoetin alfa (EPO); Erythropoiesis stimulating agents; hemoglobin variability; meta analysis; mortality; recombinant human erythropoietin (rHuEPO)

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT; ERYTHROPOIETIN; RECOMBINANT PROTEIN;

ARTICLE; CHRONIC KIDNEY DISEASE; COMPARATIVE EFFECTIVENESS; END STAGE RENAL DISEASE; FOLLOW UP; HUMAN; META ANALYSIS; MORTALITY; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; STUDY DESIGN; SYSTEMATIC REVIEW; ANALOGS AND DERIVATIVES; ANEMIA; CAUSE OF DEATH; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; COMPLICATION; DOUBLE BLIND PROCEDURE; HALF LIFE TIME; HEMODIALYSIS; KIDNEY FAILURE, CHRONIC; STATISTICS AND NUMERICAL DATA;

ANEMIA; CAUSE OF DEATH; DARBEPOETIN ALFA; DOUBLE-BLIND METHOD; EPOETIN ALFA; ERYTHROPOIETIN; HALF-LIFE; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84937518041     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2014.12.012     Document Type: Article

References (33)

1. J.M. Portoles, A.L. de Francisco, J.L. Gorriz, and et al. Maintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a historical prospective study Kidney Int Suppl 74 111S 2008 S82 S87
2. T. Kuragano, O. Matsumura, A. Matsuda, and et al. Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients Kidney Int 86 2014 845 854
3. W. Yang, R.K. Israni, S.M. Brunelli, M.M. Joffe, S. Fishbane, and H.I. Feldman Hemoglobin variability and mortality in ESRD J Am Soc Nephrol 18 2007 3164 3170
4. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease Chapter 3: use of ESAs and other agents to treat anemia in CKD Kidney Int Suppl 2 2012 299 310
5. US Food and Drug Administration. Briefing information for the October 18, 2010 meeting of the Cardiovascular and Renal Drugs Advisory Committee. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ucm229325.htm. Accessed October 25, 2010.
6. F. Locatelli, J. Olivares, R. Walker, and et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency Kidney Int 60 2001 741 747
7. M. Allon, K. Kleinman, M. Walczyk, and et al. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis Clin Pharmacol Ther 72 2002 546 555
8. A.R. Nissenson, S.K. Swan, J.S. Lindberg, and et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients Am J Kidney Dis 40 2002 110 118
9. Y. Vanrenterghem, P. Barany, J.F. Mann, and et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients Kidney Int 62 2002 2167 2175
10. W.Y. Li, T.S. Chu, J.W. Huang, M.S. Wu, and K.D. Wu Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis J Formos Med Assoc 107 2008 843 850
11. D.W. Coyne, B.N. Ling, R. Toto, A.D. McDermott-Vitak, M.L. Trotman, and L. Jackson Novel erythropoiesis stimulating protein (NESP) corrects anemia in dialysis patients when administered at reduced dose frequency compared with recombinant-human erythropoietin (r-HuEPO) [abstract] J Am Soc Nephrol 11 2000 263A
12. K. Hori, Y. Tsujimoto, H. Ohmori, and et al. Randomized, double-blind, comparative study of intravenous KRN321 (darbepoetin alfa) compared to intravenous recombinant human erythropoetin alfa (rHuEPO) for treatmet of anemia in subjects with chronic renal failure (CRF) receiving hemodialysis in Japan [abstract] J Am Soc Nephrol 15 2004 177A
13. B. Bernieh, S. Abouchacra, Y. Boobes, and et al. Comparison between short- and long-acting erythropoiesis-stimulating agents in hemodialysis patients: target hemoglobin, variability, and outcome Int Urol Nephrol 46 2014 453 459
14. Y.I. Jo, D.H. Yang, and S.K. Shin A randomized, cross-over, multicenter study of biweekly administration of high dose epoetin-A compared with darbepoetin-A in pre-ESRD patients [abstract] Nephrology 15 2010 39
15. Amgen. A randomized, double-blind study comparing Aranesp (darbepoetin alfa) and recombinant human erythropoietin (rHuEPO) in the treatment of anemia in African-American subjects with chronic renal failure (CRF) receiving hemodialysis. http://www.amgentrials.com/amgen/trialsummary.aspx?studyid=20010125. Accessed January 7, 2015.
16. C.L. Bennett, S. Jacob, J. Hymes, L.A. Usvyat, and F.W. Maddux Anaphylaxis and hypotension after administration of peginesatide N Engl J Med 370 2014 2055 2056
17. I.C. Macdougall, S.J. Gray, O. Elston, and et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients J Am Soc Nephrol 10 1999 2392 2395
18. J.C. Egrie, and J.K. Browne Development and characterization of novel erythropoiesis stimulating protein (NESP) Nephrol Dial Transplant 16 suppl 3 2001 3 13
19. D.H. Catlin, A. Breidbach, S. Elliott, and J. Glaspy Comparison of the isoelectric focusing patterns of darbepoetin alfa, recombinant human erythropoietin, and endogenous erythropoietin from human urine Clin Chem 48 2002 2057 2059
20. A.K. Singh Does TREAT give the boot to ESAs in the treatment of CKD anemia? J Am Soc Nephrol 21 2010 2 6
21. K. Maiese, F. Li, and Z.Z. Chong New avenues of exploration for erythropoietin JAMA 293 2005 90 95
22. D. Fliser, and H. Haller Erythropoietin and treatment of non-anemic conditions - cardiovascular protection Semin Hematol 44 2007 212 217
23. T.R. Lappin, A.P. Maxwell, and P.G. Johnston EPO's alter ego: erythropoietin has multiple actions Stem Cells 20 2002 485 492
24. M.J. Weiss New insights into erythropoietin and epoetin alfa: mechanisms of action, target tissues, and clinical applications Oncologist 8 suppl 3 2003 18 29
25. F.H. Bahlmann, K. DeGroot, T. Duckert, and et al. Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin Kidney Int 64 2003 1648 1652
26. F.H. Bahlmann, K. De Groot, J.M. Spandau, and et al. Erythropoietin regulates endothelial progenitor cells Blood 103 2004 921 926
27. T. Asahara, H. Masuda, T. Takahashi, and et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization Circ Res 85 1999 221 228
28. V.J. Dzau, M. Gnecchi, A.S. Pachori, F. Morello, and L.G. Melo Therapeutic potential of endothelial progenitor cells in cardiovascular diseases Hypertension 46 2005 7 18
29. M. Leist, P. Ghezzi, G. Grasso, and et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic Science 305 2004 239 242
30. F. Fiordaliso, S. Chimenti, L. Staszewsky, and et al. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury Proc Natl Acad Sci U S A 102 2005 2046 2051
31. S.C. Palmer, V. Saglimbene, D. Mavridis, and et al. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis Cochrane Database Syst Rev 12 2014 CD010590
32. Blue Cross and Blue Shield Association Technology Evaluation Center; Evidence-Based Practice Center Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment. Comparative Effectiveness Update. Comparative Effectiveness Reviews, No. 113 2013 Agency for Healthcare Research and Quality (US) Rockville, MD http://www.ncbi.nlm.nih.gov/books/NBK143013/?report=reader Accessed December 5, 2014
33. US Food and Drug Administration. Drug approval package, Mircera (methoxy polyethylene glycol-epoetin beta) injectiion, office director memo. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2007/125164s000-ODMemo.pdf. Accessed December 11, 2014.